FAM
Fred Alger Management Portfolio holdings
AUM
$22.3B
1-Year Return
57.87%
This Quarter Return
+5.77%
1 Year Return
+57.87%
3 Year Return
+264.72%
5 Year Return
+406.03%
10 Year Return
+1,631.73%
AUM
$38.2B
AUM Growth
-$214M
(-0.56%)
Cap. Flow
-$340M
Cap. Flow
% of AUM
-0.89%
Top 10 Holdings %
Top 10 Hldgs %
26.41%
Holding
533
New
69
Increased
170
Reduced
197
Closed
57
Top Buys
| 1 |
CMRC
Commerce.com, Inc. Series 1 Common Stock
CMRC
|
$252M |
| 2 |
Capri Holdings
CPRI
|
$216M |
| 3 |
MGM Resorts International
MGM
|
$197M |
| 4 |
SBNY
Signature Bank
SBNY
|
$186M |
| 5 |
Applied Materials
AMAT
|
$178M |
Top Sells
| 1 |
Meta Platforms (Facebook)
META
|
$408M |
| 2 |
T-Mobile US
TMUS
|
$398M |
| 3 |
Alibaba
BABA
|
$345M |
| 4 |
Apple
AAPL
|
$344M |
| 5 |
Salesforce
CRM
|
$300M |
Sector Composition
| 1 | Technology | 34.94% |
| 2 | Healthcare | 19.8% |
| 3 | Consumer Discretionary | 14.84% |
| 4 | Financials | 9.09% |
| 5 | Communication Services | 7.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Cheniere Energy
CQP
$26.2B
| $1.1M | ﹤0.01% |
26,416
| – | – |
|
377
Novartis
NVS
$249B
| $1.08M | ﹤0.01% |
12,591
-44
| -0.3% | -$3.76K |
|
378
Sempra
SRE
$53.6B
| $1.07M | ﹤0.01% |
16,180
| – | – |
|
379
Equinix
EQIX
$75.2B
| $1.07M | ﹤0.01% |
1,568
| – | – |
|
380
Adaptive Biotechnologies
ADPT
$1.98B
| $1.05M | ﹤0.01% |
26,105
-20,033
| -43% | -$807K |
|
381
GSK
GSK
$79.8B
| $1.05M | ﹤0.01% |
23,466
| – | – |
|
|
YSG
382
Yatsen Holding
YSG
$825M
| $1.04M | ﹤0.01% |
+16,800
| New | +$1.04M |
|
383
Aptiv
APTV
$17.5B
| $1.04M | ﹤0.01% |
7,512
+1,638
| +28% | +$226K |
|
384
Hartford Financial Services
HIG
$37.9B
| $1.03M | ﹤0.01% |
15,349
| – | – |
|
|
CONE
385
DELISTED
CyrusOne Inc Common Stock
CONE
| $999K | ﹤0.01% |
14,754
| – | – |
|
386
argenx
ARGX
$44.9B
| $988K | ﹤0.01% |
3,589
-3,682
| -51% | -$1.01M |
|
387
ASML
ASML
$296B
| $978K | ﹤0.01% |
1,584
-13
| -0.8% | -$8.03K |
|
388
New Oriental
EDU
$7.98B
| $965K | ﹤0.01% |
6,890
+390
| +6% | +$54.6K |
|
389
Progressive
PGR
$146B
| $963K | ﹤0.01% |
10,070
+3,745
| +59% | +$358K |
|
390
Denali Therapeutics
DNLI
$2.16B
| $950K | ﹤0.01% |
16,634
-244
| -1% | -$13.9K |
|
391
Philip Morris
PM
$251B
| $943K | ﹤0.01% |
10,631
| – | – |
|
392
Dianthus Therapeutics
DNTH
$794M
| $941K | ﹤0.01% |
+4,969
| New | +$941K |
|
393
Gilead Sciences
GILD
$140B
| $921K | ﹤0.01% |
14,248
-203
| -1% | -$13.1K |
|
394
Viatris
VTRS
$12B
| $910K | ﹤0.01% |
65,159
-82,600
| -56% | -$1.15M |
|
395
StoneCo
STNE
$4.42B
| $859K | ﹤0.01% |
14,034
+740
| +6% | +$45.3K |
|
396
Dow Inc
DOW
$16.9B
| $820K | ﹤0.01% |
12,828
| – | – |
|
397
Palo Alto Networks
PANW
$129B
| $806K | ﹤0.01% |
15,012
-66,738
| -82% | -$3.58M |
|
398
MSCI
MSCI
$43.1B
| $797K | ﹤0.01% |
1,900
+500
| +36% | +$210K |
|
399
Freeport-McMoran
FCX
$66.1B
| $790K | ﹤0.01% |
+24,000
| New | +$790K |
|
400
Oneok
OKE
$46.8B
| $790K | ﹤0.01% |
15,600
| – | – |
|